This website uses technical, customisation and analytical cookies, both first-party and third-party, to anonymously facilitate browsing and analyse statistics on use of the website. Learn more
Search results
-
The RealReal Inc.: Fashion Fad or Long-Term Investment
Shernaz Bodhanwala; Ruzbeh BodhanwalaCase IVEY-9B20N035-EEntrepreneurship, Finance, StrategyThe RealReal Inc. (Real), a San Francisco, California-based start-up engaged in the trade of used luxury goods, experienced significant growth in its revenue and customer base in fiscal year (FY) 2018, but it was yet to turn profitable after nine years inStarting at €8.20
-
Tata Motors: The Dividend Dilemma
Shernaz Bodhanwala; Ruzbeh BodhanwalaCase IVEY-W30443-EFinance, StrategyTata Motors Limited (Tata Motors), an Indian automobile major with a consolidated annual turnover of more than ₹2,497 billion in fiscal year (FY) 2021, was struggling to turn profitable and reinstate dividend payments to its investors. The case discusses the dividend policy of Tata Motors, comparing it with the dividend policies of the company’s peers and examining its relevance to the investor community at large. With Tata Motors’ long history a...Starting at €8.20
-
HUL’s Acquisition of GSK Consumer Healthcare: A Hefty Rise in Intangible Assets
Shernaz Bodhanwala; Ruzbeh BodhanwalaCase IVEY-W33460-EAccounting and Control, StrategyIn January 2019, the Competition Commission of India approved a significant merger in India’s fast-moving consumer goods industry. The merger between Hindustan Unilever Limited (HUL) and GlaxoSmithKline Consumer Healthcare Limited (GSKCONS) took place in April 2020. The deal helped HUL strengthen its food and refreshments business and diversify into the health food drinks market. The hefty purchase price paid for the merger led HUL to record mass...Starting at €8.20
-
Tata Motors: Can the Turnaround Plan improve Performance
Shernaz Bodhanwala; Ruzbeh BodhanwalaCase IVEY-9B20N001-EFinance, StrategyTata Motors Limited, an Indian automobile manufacturer, had been struggling with decreasing market share and profitability, which was affecting the company's share price. After the appointment of a new chief executive officer in 2016, the company undertook several reorganization programs to revive its financial health and improve its market share. However, it still registered heavy losses in the first nine months of fiscal year 2018–19. Was there...Starting at €8.20
-
Turing Pharmaceuticals: The Ethics of Drug Pricing
Shernaz Bodhanwala; Aakash BothraCase IVEY-9B17M167-EStrategyIn 2015 there was a public outcry over the price increase in Daraprim (pyrimethamine) by Turing Pharmaceuticals AG (Turing). Daraprim was a drug that was widely used by a small population of U.S. patients to treat toxoplasmosis. Soon after Turing acquired its commercialization rights in August 2015, the company increased the list price of the drug by over 5,000 per cent. The increase led to consumer protests in the United States, and the media ve...Starting at €8.20